GHP Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

GHP Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.7K	Hold	33	–	–	﹤0.01%	706
2026 Q1	$25.6K	Buy	33 +1	+3%	+$766	﹤0.01%	657
2025 Q4	$24.8K	Hold	32	–	–	﹤0.01%	621
2025 Q3	$18K	Hold	32	–	–	﹤0.01%	646
2025 Q2	$16.8K	Sell	32 -5	-14%	-$2.79K	﹤0.01%	656
2025 Q1	$23.5K	Buy	37 +3	+9%	+$2.06K	﹤0.01%	582
2024 Q4	$24.2K	Buy	34 +14	+70%	+$11.7K	﹤0.01%	576
2024 Q3	$21K	Hold	20	–	–	﹤0.01%	613
2024 Q2	$21K	Hold	20	–	–	﹤0.01%	586
2024 Q1	$19.3K	Hold	20	–	–	﹤0.01%	591
2023 Q4	$17.6K	Hold	20	–	–	﹤0.01%	592
2023 Q3	$16.8K	Hold	20	–	–	﹤0.01%	624
2023 Q2	$16.1K	Hold	20	–	–	﹤0.01%	616
2023 Q1	$16.4K	Sell	20 -6	-23%	-$4.53K	﹤0.01%	608
2022 Q4	$18.8K	Hold	26	–	–	﹤0.01%	596
2022 Q3	$18K	Buy	26 +6	+30%	+$3.78K	﹤0.01%	592
2022 Q2	$12K	Hold	20	–	–	﹤0.01%	652
2022 Q1	$14K	Buy	+20	New	+$12.7K	﹤0.01%	664

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

GHP Investment Advisors's REGN Position: Q2 2026 in Review

GHP Investment Advisors held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 33 shares worth $20.7K. The position accounts for ﹤0.01% of the portfolio, ranked #706.

GHP Investment Advisors first reported a position in REGN in Q1 2022 and has held it in 18 quarters since. The position peaked at $25.6K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

GHP Investment Advisors held 33 shares of Regeneron Pharmaceuticals worth $20.7K as of Q2 2026.
GHP Investment Advisors left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up ﹤0.01% of GHP Investment Advisors's portfolio in Q2 2026, its #706 holding.
GHP Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
GHP Investment Advisors's Regeneron Pharmaceuticals position peaked at $25.6K in Q1 2026.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on GHP Investment Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.